title: Electrophysiological profile of propiverine--relationship to cardiac risk.
abstract: Drugs that prolong the QT interval by blocking human ether-a-go-go (HERG) channels may enhance the risk of ventricular arrhythmia. The spasmolytic drug propiverine is widely used for the therapy of overactive bladder (OAB). Here, we have investigated the effects of propiverine on cardiac ion channels and action potentials as well as on contractile properties of cardiac tissue, in order to estimate its cardiac safety profile, because other drugs used in this indication had to be withdrawn due to safety reasons. Whole-cell patch clamp technique was used to record the following cardiac ion currents: rapidly and slowly activating delayed rectifier K+ current (I(Kr), I(Ks)), ultra rapidly activating delayed rectifier K+ current (I(Kur)), inwardly rectifying K+ current I(K1), transient outward K+ current (I(to)), and L-type Ca2+ current (I(Ca,L)). Action potentials in cardiac tissue biopsies were recorded with conventional microelectrodes. The torsade de pointes screening assay (TDPScreen) was used for drug scoring. Propiverine blocked in a concentration-dependent manner HERG channels expressed in HEK293 cells, as well as native I(Kr) current in ventricular myocytes of guinea pig (IC50 values: 10 microM and 1.8 microM respectively). At high concentrations (100 microM), propiverine suppressed I(Ks). I(K1) and the transient outward current I(to) and I(Kur) were not affected. In guinea-pig ventricular and human atrial myocytes, propiverine also blocked I(Ca,L) (IC50 values: 34.7 microM and 41.7 microM, respectively) and reduced force of contraction. Despite block of I(Kr), action potential duration was not prolonged in guinea-pig and human ventricular tissue, but decreased progressively until excitation failed altogether. Similar effects were observed in dog Purkinje fibers. Propiverine obtained a low score in the TDPScreen. In conclusion, in vitro and in vivo studies of propiverine do not provide evidence for an enhanced cardiovascular safety risk. We propose that lack of torsadogenic risk of propiverine is related to enhancement of repolarization reserve by block of I(Ca,L).
authors: Department of Pharmacology and Toxicology, Medical Faculty, Dresden University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany.
authors: Torsten
authors: T
authors: Christ
authors: Erich
authors: E
authors: Wettwer
authors: Melinda
authors: M
authors: Wuest
authors: Manfred
authors: M
authors: Braeter
authors: Frank
authors: F
authors: Donath
authors: Pascal
authors: P
authors: Champeroux
authors: Serge
authors: S
authors: Richard
authors: Ursula
authors: U
authors: Ravens
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001561:Benzilates / Q000009:adverse effects* / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000502:physiology*; D002460:Cell Line; D016208:Databases, Factual; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D051638:Ether-A-Go-Go Potassium Channels / Q000502:physiology; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D010276:Parasympatholytics / Q000009:adverse effects* / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D015221:Potassium Channels / Q000502:physiology*; D016171:Torsades de Pointes / Q000139:chemically induced
chemical_list: D001561:Benzilates; D020746:Calcium Channels, L-Type; D051638:Ether-A-Go-Go Potassium Channels; D010276:Parasympatholytics; D015221:Potassium Channels; C015586:propiverine